Jaguar Animal Health Inc Net Assets
Jaguar Animal Health Inc net assets. Based on the latest financial reports, Jaguar Animal Health Inc (JAGX) has net assets worth $4.92 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.19 Million) and total liabilities ($29.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Jaguar Animal Health Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.92 Million |
| % of Total Assets | 14.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -257.66% |
| 10-Year Change | N/A |
| Growth Volatility | 172.05 |
Net Assets of Jaguar Animal Health Inc (2007–2025)
Net assets of Jaguar Animal Health Inc from 2007 to 2025. This chart illustrates how Jaguar Animal Health Inc's net assets have evolved over time, based on quarterly financial data. See JAGX equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Jaguar Animal Health Inc (2007–2025)
The table below shows the annual net assets of Jaguar Animal Health Inc from 2007 to 2025. For live market cap and overall valuation, see JAGX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-18.69 Million | -387.77% |
| 2024-12-31 | $6.49 Million | +32.61% |
| 2023-12-31 | $4.90 Million | +461.14% |
| 2022-12-31 | $-1.36 Million | -111.44% |
| 2021-12-31 | $11.85 Million | -31.10% |
| 2020-12-31 | $17.20 Million | +61.17% |
| 2019-12-31 | $10.67 Million | +98.27% |
| 2018-12-31 | $5.38 Million | -68.81% |
| 2017-12-31 | $17.26 Million | +803.33% |
| 2016-12-31 | $-2.45 Million | -155.79% |
| 2015-12-31 | $4.40 Million | +301.29% |
| 2014-12-31 | $1.10 Million | +352.09% |
| 2013-12-31 | $-434.85K | -108.05% |
| 2007-12-31 | $5.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jaguar Animal Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35083684900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Jaguar Animal Health Inc Net Assets Breakdown (December 2025)
Jaguar Animal Health Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-833.00K | % |
| Other Components | $383.46 Million | % |
| Total Equity | $-17.29 Million | 100.00% |
Jaguar Animal Health Inc Competitors by Market Cap
The table below lists competitors of Jaguar Animal Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shree Ram Proteins Limited
NSE:SRPL
|
$787.61K |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
$788.53K |
|
Tessin Nordic Holding AB
ST:TESSIN
|
$789.48K |
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
$794.86K |
|
Europejskie Centrum Odszkodowań SA
WAR:EUC
|
$786.01K |
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
$783.04K |
|
Strix Group Plc
LSE:KETL
|
$782.57K |
|
Speedy Hire PLC
LSE:SDY
|
$781.48K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jaguar Animal Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,285,000 to -17,289,000, a change of -24,574,000 (-337.3%).
- Net loss of 53,434,000 reduced equity.
- Share repurchases of 31,066,000 reduced equity.
- New share issuances of 10,977,000 increased equity.
- Other comprehensive income decreased equity by 366,000.
- Other factors increased equity by 49,315,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.43 Million | -309.06% |
| Share Repurchases | $31.07 Million | -179.69% |
| Share Issuances | $10.98 Million | +63.49% |
| Other Comprehensive Income | $-366.00K | -2.12% |
| Other Changes | $49.31 Million | +285.24% |
| Total Change | $- | -337.32% |
Book Value vs Market Value Analysis
This analysis compares Jaguar Animal Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.00 | $0.40 | x |
| 2015-12-31 | $0.00 | $0.40 | x |
| 2016-12-31 | $0.00 | $0.40 | x |
| 2017-12-31 | $0.00 | $0.40 | x |
| 2018-12-31 | $0.00 | $0.40 | x |
| 2019-12-31 | $152471428.57 | $0.40 | x |
| 2020-12-31 | $78190909.09 | $0.40 | x |
| 2021-12-31 | $15277631.58 | $0.40 | x |
| 2022-12-31 | $-393413.17 | $0.40 | x |
| 2023-12-31 | $171068.97 | $0.40 | x |
| 2024-12-31 | $12985.74 | $0.40 | x |
| 2025-12-31 | $-3891.29 | $0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jaguar Animal Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -464.20%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-363.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -472.62% | -8416.39% | 0.03x | 1.91x | $-26.07 Million |
| 2014 | -785.38% | 0.00% | 0.00x | 5.25x | $-8.72 Million |
| 2015 | -370.34% | -6305.24% | 0.02x | 2.82x | $-16.73 Million |
| 2016 | 0.00% | -10410.87% | 0.04x | 0.00x | $-14.49 Million |
| 2017 | -127.27% | -503.73% | 0.10x | 2.53x | $-23.69 Million |
| 2018 | -597.16% | -727.92% | 0.11x | 7.62x | $-32.68 Million |
| 2019 | -361.09% | -667.34% | 0.16x | 3.41x | $-39.61 Million |
| 2020 | -196.54% | -360.25% | 0.22x | 2.49x | $-35.53 Million |
| 2021 | -452.98% | -1213.26% | 0.08x | 4.59x | $-53.76 Million |
| 2022 | 0.00% | -396.91% | 0.25x | 0.00x | $-47.39 Million |
| 2023 | -832.49% | -423.11% | 0.19x | 10.23x | $-41.80 Million |
| 2024 | -528.37% | -329.30% | 0.22x | 7.33x | $-39.22 Million |
| 2025 | 0.00% | -464.20% | 0.30x | 0.00x | $-51.71 Million |
Industry Comparison
This section compares Jaguar Animal Health Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $194,529,907
- Average return on equity (ROE) among peers: -57.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jaguar Animal Health Inc (JAGX) | $4.92 Million | -472.62% | 5.95x | $786.58K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $966.90 Million | -15.14% | 0.40x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $16.14 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $10.73 Million | -115.68% | 0.96x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $-1.24 Million | 0.00% | 0.00x | $25.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.66 Billion |
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. I… Read more